首页> 外文OA文献 >A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer

【2h】

A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer

机译：Aurora和血管生成激酶抑制剂ENMD-2076的II期临床试验，用于先前治疗，先进或转移性三重阴性乳腺癌

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Jennifer R. Diamond; S. G. Eckhardt; Todd M. Pitts; Adrie van Bokhoven; Dara Aisner; Daniel L. Gustafson; Anna Capasso; Sharon Sams; Peter Kabos; Kathryn Zolman; Tiffany Colvin; Anthony D. Elias; Anna M. Storniolo; Bryan P. Schneider; Dexiang Gao; John J. Tentler; Virginia F. Borges; Kathy D. Miller;
展开▼
作者单位

展开▼
年度 2018
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Efficacy and Molecular Mechanisms of Differentiated Response to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Models of p53-Mutated Triple-Negative Breast Cancer [J] . Anastasia A. Ionkina, John J. Tentler, Jihye Kim, Frontiers in Oncology . 2017,第8期

机译：在p53突变的三阴性乳腺癌临床前模型中对极光和血管生成激酶抑制剂ENMD-2076的差异反应的功效和分子机制
2. Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in patients with advanced solid tumors. [J] . Diamond JR, Bastos BR, Hansen RJ, Clinical cancer research: an official journal of the American Association for Cancer Research . 2011,第4期

机译：ENMD-2076（一种新型的血管生成和Aurora激酶抑制剂）在患有晚期实体瘤的患者中进行I期安全性，药代动力学和药效学研究。
3. Predictive biomarkers of sensitivity to the Aurora and angiogenic kinase inhibitor ENMD-2076 in preclinical breast cancer models [J] . DiamondJ.R., EckhardtS.G., TanA.C., Clinical cancer research: an official journal of the American Association for Cancer Research . 2013,第1期

机译：临床前乳腺癌模型中对Aurora和血管生成激酶抑制剂ENMD-2076敏感性的预测生物标志物
4. Phase I/II clinical trials on the effect of weekly paclitaxel (wPTX) and wPTX containing combination regimens for advanced and metastatic gastric cancer -ECRIN group studies [C] . Sakamoto J, Kodera Y, Kobayashi M, International Gastric Cancer Congress . 2009

机译：I / II期临床试验关于每周紫杉醇（WPTX）和WPTX含有晚期和转移性胃癌组合方案的临床试验 - 分泌组研究
5. Predictive Biomarkers of the Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treating Advanced Non-small Cell Lung Cancer: A Systematic Review of Randomized Controlled Trials [D] . Yang, Zuyao. 2014

机译：表皮生长因子受体酪氨酸激酶抑制剂治疗晚期非小细胞肺癌疗效的预测生物标志物：随机对照试验的系统评价。
6. A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated advanced or metastatic triple-negative breast cancer [O] . Jennifer R. Diamond, S. G. Eckhardt, Todd M. Pitts, 2018

机译：Aurora和血管生成激酶抑制剂ENMD-2076在先前治疗晚期或转移性三阴性乳腺癌中的II期临床试验
7. Efficacy and Molecular Mechanisms of Differentiated Response to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Models of p53-Mutated Triple-Negative Breast Cancer [O] . Anastasia A. Ionkina, John J. Tentler, Jihye Kim, 2017

机译：p53突变三阴性乳腺癌临床前模型中极光和血管生成激酶抑制剂ENmD-2076分化应答的功效和分子机制

A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer

著录项

引文网络

相似文献

相关主题

期刊订阅